• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH MULTIFIBRIN U

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH MULTIFIBRIN U Back to Search Results
Catalog Number OWZG
Device Problem Incorrect Or Inadequate Test Results (2456)
Patient Problem No Known Impact Or Consequence To Patient (2692)
Event Date 05/25/2015
Event Type  malfunction  
Event Description
A falsely depressed, flagged fibrinogen result was obtained on a patient sample.The depressed, flagged patient result was reported to the physicians who eventually questioned the result.The repeat test of the sample provided a higher result in the normal reference range.Patient treatment was altered or prescribed on the basis of the falsely depressed fibrinogen result.Fresh frozen plasma and cryoprecipitate were administered before the physician questioned the result.The patient experienced a thrombotic event.They patient was further treated to reverse the effects of the cryoprecipitate treatment.The account has noted that the patient is ok after that treatment.
 
Manufacturer Narrative
The cause of the discrepant falsely depressed fibrinogen result is a known susceptibility of the multifibrin u reagent.The falsely depressed level appears to be related to the patient's medication.The sample result was accompanied by the comment "results doubtful" and the analyzer operated as intended.Per the bcs xp operator's guide this comment flag does not preclude result reporting but would alert the operator to investigate further.The patient is on argatroban therapy, which can lead to falsely depressed fibrinogen levels.Argatroban is a direct thrombin inhibitor.Multifibrin u reagent contains bovine thrombin.The principle of the fibrinogen with mfu assay is " citrated plasma is brought to coagulation by a large excess of thrombin." incorporating a medication that is intended to inhibit the function of thrombin can lead to interference in these assays.Documented in the multifibrin u instructions for use, limitations of the procedure section is the statement: "therapy with direct thrombin inhibitors, e.G.Hirudin, may contribute to diminished recovery." the device is performing within specifications.No further evaluation of the device is required.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
MULTIFIBRIN U
Type of Device
MULTIFIBRIN U
Manufacturer (Section D)
SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH
76 emil von behring strasse
marburg, 3504 1
GM  35041
Manufacturer (Section G)
SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH
76 emil von behring strasse
marburg, 3504 1
GM   35041
Manufacturer Contact
james morgera
glasgow business community
po box 6101
newark, DE 19714-6101
3026318356
MDR Report Key4856067
MDR Text Key5852356
Report Number9610806-2015-00013
Device Sequence Number1
Product Code KQJ
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K934326
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Health Professional,User Facility
Reporter Occupation Medical Technologist
Type of Report Initial
Report Date 05/26/2015
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received06/19/2015
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Medical Technologist
Device Catalogue NumberOWZG
Device Lot NumberNOT PROVIDED
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received05/26/2015
Was Device Evaluated by Manufacturer? No
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Other;
-
-